New combo therapy aims to extend life in advanced lung cancer
NCT ID NCT07567313
First seen May 08, 2026 · Last updated May 08, 2026
Summary
This study tests whether adding a targeted procedure called bronchial artery chemoembolization to standard immunotherapy can help people with stage IV lung squamous cell carcinoma live longer without their cancer growing. About 166 adults who have already responded to initial treatment will be randomly assigned to receive either immunotherapy alone or immunotherapy plus the procedure. The goal is to see if the combination improves progression-free survival and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG SQUAMOUS CELL CARCINOMA STAGE IV are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.